eccogene glp-1 obtains exclusive license from AstraZeneca to develop and sell ECC5004, a receptor agonist for cardio-metabolic diseases AstraZeneca stays in GLP-1 drug

Nausea, vomiting, and diarrhea are commonly associated with GLP1 drugs, but other more serious complications can occur

Train Front Desk and Patient Coordinators Give non-clinical staff clear scripts on what they can and cant say about meds, prices, eligibility, or weight loss Clinical questions should always go to clinical staff Business Risks if You Ignore These Rules Not following the new policies can snowball into bigger problems

Why is Trulicity not approved for weight loss

These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost, CMS Administrator Dr

Trying to decide between two